IDRA-21 — Safety, Research, Risks & Legal Status

Not medical advice. IDRA-21 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide; CAS 22503-72-6; Idalian/Cortex ampakine compound
Category	Research Chemical
CAS Number	22503-72-6
Drug Class	Benzothiadiazine ampakine; AMPA receptor positive allosteric modulator (second-generation)
Development Status	Preclinical only; discontinued ~2003; no human trials ever conducted
Primary Developers	UC Irvine (origin), Cortex Pharmaceuticals, Fidia Farmaceutici
Comparative Potency (animal)	10-30x more potent than aniracetam in rodent reversal models; more potent than CX-516, less than CX-546
Effect Duration (rodent)	Up to 48 hours post-administration in some passive-avoidance protocols
US legal status	Not approved for human use in the United States. IDRA-21 is an uncontrolled preclinical research chemical. It holds no FDA approval, no active IND pathway, and development was discontinued circa 2003. It is sold commercially only under "not for human consumption" research-use labeling. Possession is not federally scheduled, but human use is without any regulatory sanction.

What is IDRA-21?

IDRA-21 is a second-generation benzothiadiazine AMPA receptor positive allosteric modulator (ampakine) developed in the early 1990s from UC Irvine medicinal chemistry work and later carried through preclinical stages by Cortex Pharmaceuticals and Fidia Farmaceutici. It was investigated in animal models as a potential cognitive enhancer, particularly for deficits associated with aging, pharmacological impairment, and ischemic injury. All human use is unsupported by clinical evidence; development was halted by 2003 and no human trials have ever been conducted.

How it works

IDRA-21 slows AMPA receptor desensitization and deactivation, prolonging and amplifying excitatory postsynaptic current without acting as a direct agonist. This positive allosteric modulation increases the probability and duration of AMPA receptor channel opening in response to glutamate. Downstream effects observed in animal studies include enhanced induction of hippocampal long-term potentiation (LTP) and increased BDNF release in hippocampal tissue. Only the active stereoisomer produces behavioral effects, indicating stereoselective binding at the target site.

Background & history

Medicinal chemistry work at UC Irvine in the early 1990s produced the benzothiadiazine ampakine series. IDRA-21 emerged as a potent representative and was subsequently licensed into Cortex Pharmaceuticals' broader ampakine development program, which also generated CX-516, CX-546, and related compounds. Fidia Farmaceutici (Italy) independently investigated it for cognitive disorders of aging and ischemia. Despite promising preclinical signals in rodents and non-human primates, development was formally discontinued around 2003. No regulatory filing for human trials was ever pursued in the US or EU. The compound now exists only as a commercially available research chemical with no active pharmaceutical sponsor.

What the research says

All evidence is preclinical; no human trials exist and none are registered on ClinicalTrials.gov. In rodent models, IDRA-21 produced dose-dependent improvements in acquisition, consolidation, and retrieval across passive-avoidance and delayed-matching-to-sample paradigms. It reversed alprazolam- and scopolamine-induced cognitive deficits at potencies reported as 10-30x greater than aniracetam. Effects persisted up to 48 hours post-administration in some rodent protocols. In non-human primates (young and aged rhesus monkeys), it improved visual recognition memory and delayed-matching performance. Comparative potency within the Cortex ampakine series places it above CX-516 but below CX-546. These findings cannot be extrapolated to human efficacy or safety without clinical trial data, which does not exist.

Reported effects

Dose-dependent improvement in acquisition and retrieval in rodent passive-avoidance and delayed-matching tasks (animal data only)
Reversal of alprazolam- and scopolamine-induced cognitive deficits in rodents (animal data only, 10-30x more potent than aniracetam in these models)
Enhanced hippocampal long-term potentiation magnitude (animal data only)
Improved visual recognition memory and delayed-matching performance in young and aged rhesus monkeys (non-human primate data only)
Prolonged duration of effect relative to earlier ampakines, with activity reported up to 48 hours post-dose in rodent studies
No demonstrated effects in humans; human pharmacodynamics are entirely unknown

Dosing & administration (informational)

Animal studies used doses producing an approximate ED50 of 7.6 µM in rodent water maze and passive-avoidance tasks; mg/kg values from published protocols are available in the primary literature (PubMed: 7815345). These figures are species-specific and cannot be allometrically converted to a human dose without human pharmacokinetic data, which does not exist. No safe or effective dose for humans has ever been established. This information is provided for reference to the published literature only and is not a dosing protocol. Anyone considering any use should consult a licensed clinician.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Human safety profile is completely unknown; no clinical pharmacology, toxicology, or tolerability data from human subjects exists
Primary mechanistic concern is excitotoxicity: amplification of AMPA receptor signaling can potentiate glutamate-mediated neuronal injury
In vitro: IDRA-21 combined with exogenous glutamate caused death of rat hippocampal neurons via AMPA-mediated excitotoxicity
Animal ischemia data: may worsen neuronal damage following global ischemia; contraindicated in stroke or seizure risk contexts based on preclinical signals
No neurotoxicity was observed under normal (non-ischemic) dosing conditions in animal studies, but this cannot be assumed to generalize to humans
Anecdotal reports from uncontrolled human use describe increased aggression and emotional lability at doses as low as 10 mg; these reports are entirely unverified and carry no clinical weight
Development discontinued with no regulatory pathway pursued; risk-benefit profile in humans remains uncharacterized

Drug & supplement interactions

N
o
h
u
m
a
n
p
h
a
r
m
a
c
o
k
i
n
e
t
i
c
o
r
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
e
x
i
s
t
s
.
M
e
c
h
a
n
i
s
t
i
c
a
l
l
y
,
a
n
y
a
g
e
n
t
t
h
a
t
i
n
c
r
e
a
s
e
s
g
l
u
t
a
m
a
t
e
r
g
i
c
t
o
n
e
(
r
a
c
e
t
a
m
s
,
o
t
h
e
r
a
m
p
a
k
i
n
e
s
,
N
M
D
A
c
o
-
a
g
o
n
i
s
t
s
)
c
o
u
l
d
c
o
m
p
o
u
n
d
e
x
c
i
t
o
t
o
x
i
c
i
t
y
r
i
s
k
.
A
g
e
n
t
s
t
h
a
t
r
e
d
u
c
e
A
M
P
A
r
e
c
e
p
t
o
r
a
c
t
i
v
i
t
y
(
b
a
r
b
i
t
u
r
a
t
e
s
,
b
e
n
z
o
d
i
a
z
e
p
i
n
e
s
)
m
a
y
b
l
u
n
t
o
r
m
a
s
k
e
f
f
e
c
t
s
o
b
s
e
r
v
e
d
i
n
a
n
i
m
a
l
r
e
v
e
r
s
a
l
s
t
u
d
i
e
s
.
S
t
i
m
u
l
a
n
t
s
o
r
o
t
h
e
r
n
e
u
r
o
a
c
t
i
v
e
c
o
m
p
o
u
n
d
s
c
o
u
l
d
i
n
t
e
r
a
c
t
u
n
p
r
e
d
i
c
t
a
b
l
y
g
i
v
e
n
t
h
e
a
b
s
e
n
c
e
o
f
h
u
m
a
n
P
K
d
a
t
a
.
T
h
e
s
e
a
r
e
t
h
e
o
r
e
t
i
c
a
l
e
x
t
r
a
p
o
l
a
t
i
o
n
s
f
r
o
m
m
e
c
h
a
n
i
s
m
,
n
o
t
e
s
t
a
b
l
i
s
h
e
d
c
l
i
n
i
c
a
l
i
n
t
e
r
a
c
t
i
o
n
s
.

Who should avoid it

Any history of seizure disorder (excitotoxicity risk is mechanistically elevated)
Any stroke history or acute cerebrovascular risk (preclinical ischemia data suggests potential for worsening neuronal injury)
Concurrent use of other glutamatergic agents or ampakines (additive excitotoxicity risk, theoretical)
Pregnancy and lactation (no safety data in any species for reproductive toxicity)
Use in absence of physician oversight given completely uncharacterized human safety profile
Any context where psychomotor or emotional stability is required (unverified anecdotal aggression reports, mechanism plausibly consistent)

How it is commonly combined

No controlled evidence supports any specific combination in humans. In animal research, IDRA-21 was typically studied as a monotherapy or in reversal paradigms (against scopolamine or alprazolam). Combining with other positive AMPA modulators or glutamatergic agents amplifies theoretical excitotoxicity risk. No stacking protocol can be responsibly described given the absence of human data.

Legal & regulatory. Not approved for human use in the United States. IDRA-21 is an uncontrolled preclinical research chemical. It holds no FDA approval, no active IND pathway, and development was discontinued circa 2003. It is sold commercially only under "not for human consumption" research-use labeling. Possession is not federally scheduled, but human use is without any regulatory sanction.

Quality & harm reduction

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find IDRA-21 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Has IDRA-21 ever been tested in humans?

No. All evidence is from rodent and non-human primate studies. No human clinical trials have ever been initiated or registered. The human pharmacology, safety profile, and effective dose are completely unknown.

What dose should I take?

This cannot be answered. No safe or effective human dose has ever been established. The animal literature reports ED50 values in rodents, but species-specific pharmacokinetics make these figures non-transferable to humans without clinical PK data that does not exist. Consult a licensed clinician before considering any use of an uninvestigated research chemical.

Why was development stopped?

Cortex Pharmaceuticals discontinued the IDRA-21 program around 2003. Public records do not detail a single stated reason, but the broader Cortex ampakine pipeline faced challenges including difficulty translating animal efficacy signals into human trial outcomes across multiple compounds in the series.

Is IDRA-21 legal to buy in the US?

It is not federally scheduled and its purchase for research purposes is not prohibited. However, it is not approved for human use, holds no regulatory status as a supplement or drug, and commercial sellers label it explicitly not for human consumption. Legal to possess as a research chemical does not mean safe or sanctioned for self-administration.

How does IDRA-21 compare to aniracetam or other racetams?

IDRA-21 and aniracetam both modulate AMPA receptors, but IDRA-21 is a structurally distinct benzothiadiazine compound and was reported as 10-30 times more potent than aniracetam in rodent reversal paradigms. Aniracetam has a longer human-use history and some clinical study data, whereas IDRA-21 has none. The comparison is mechanistically informative but clinically meaningless given the absence of human data for IDRA-21.

Could IDRA-21 cause seizures or brain damage?

The primary mechanistic concern is excitotoxicity. In vitro data show that IDRA-21 combined with glutamate causes hippocampal neuron death. Preclinical ischemia data suggest it may worsen neuronal injury following stroke-like events. Whether it causes seizures or lasting injury in otherwise healthy humans at any dose is unknown, but the mechanism provides a plausible pathway for harm in vulnerable individuals or at supratherapeutic exposures.

References & further reading

PubMed: 7815345 (original 1995 benzothiadiazine AMPA mechanism characterization, Journal of Pharmacology and Experimental Therapeutics)
PubMed: 15111017 (AMPA/NMDA receptor interactions in cerebellar neurons)
PubMed: 21185313 (non-human primate visual recognition memory study)
US Patent 5,488,049 (benzothiadiazide derivatives as nootropic agents - USPTO)
ClinicalTrials.gov: search 'IDRA-21' yields no registered trials, confirming no human studies initiated